Safety of biologics in severe asthmatic patients with SARS-CoV-2 infection: A prospective study.

Sara Manti Alessandro GiallongoGiulia PecoraGiuseppe Fabio ParisiMaria PapaleEnza MulèDonatella AloisioNovella RotoloSalvatore Leonardi

Published in: Pediatric pulmonology (2023)

We showed that the scheduled dose of the biologic therapy can be administered safely on time in patients with SARS-CoV-2 infection, as the treatment did not result in adverse events or outcomes.

Keyphrases

respiratory syndrome coronavirus
rheumatoid arthritis
early onset
type diabetes
stem cells
adipose tissue
mesenchymal stem cells
cystic fibrosis
bone marrow